Non-IBD immunological diseases are a risk factor for reduced survival in PSC

Liver International

Volumn 33, Issue 1, 2013, Pages 86-93

  Rupp, Christian ^a   Mummelthei, Anne ^a   Sauer, Peter ^a   Weiss, Karl H ^a   Schirmacher, Peter ^a   Stiehl, Adolf ^a   Stremmel, Wolfgang ^a   Gotthardt, Daniel N ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Autoimmune liver disease; Biliary tract; Cholestatic liver disease; Primary sclerosing cholangitis

Indexed keywords

URSODEOXYCHOLIC ACID;

ADULT; ANEMIA; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; AUTOIMMUNE THYROIDITIS; CELIAC DISEASE; COHORT ANALYSIS; DISEASE ASSOCIATION; ENTERITIS; FEMALE; FOLLOW UP; HUMAN; IMMUNOPATHOLOGY; INFLAMMATORY DISEASE; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; PRIMARY SCLEROSING CHOLANGITIS; PROGNOSIS; PROSPECTIVE STUDY; PSORIASIS; RISK FACTOR; SACROILIITIS; SARCOIDOSIS; VASCULITIS;

ADULT; AUTOIMMUNE DISEASES; CHI-SQUARE DISTRIBUTION; CHOLAGOGUES AND CHOLERETICS; CHOLANGITIS, SCLEROSING; DIABETES MELLITUS, TYPE 1; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFLAMMATION; KAPLAN-MEIER ESTIMATE; LIVER TRANSPLANTATION; MALE; MULTIVARIATE ANALYSIS; PREVALENCE; PROPORTIONAL HAZARDS MODELS; PSORIASIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SARCOIDOSIS; TERTIARY CARE CENTERS; THYROIDITIS, AUTOIMMUNE; TIME FACTORS; URSODEOXYCHOLIC ACID;

EID: 84870834720     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12028     Document Type: Article

References (36)

1. Chapman RW, Arborgh BA, Rhodes JM, et al. Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology. Gut 1980; 21: 870-7.
2. Wiesner RH, LaRusso NF. Clinicopathologic features of the syndrome of primary sclerosing cholangitis. Gastroenterology 1980; 79: 200-6.
3. Lee YM, Kaplan MM. Primary sclerosing cholangitis. N Engl J Med 1995; 332: 924-33.
4. Talwalkar JA, Lindor KD. Natural history and prognostic models in primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol 2001; 15: 563-75.
5. Aron JH, Bowlus CL. The immunobiology of primary sclerosing cholangitis. SeminImmunopathol 2009; 31: 383-397.
6. Worthington J, Cullen S, Chapman R. Immunopathogenesis of primary sclerosing cholangitis. Clin Rev Allergy Immunol 2005; 28: 93-103.
7. Weismuller TJ, Wedemeyer J, Kubicka S, Strassburg CP, Manns MP. The challenges in primary sclerosing cholangitis-aetiopathogenesis, autoimmunity, management and malignancy. J Hepatol 2008; 48 (Suppl. 1): S38-57.
8. Witebsky E, Rose NR, Terplan K, Paine JR, Egan RW. Chronic thyroiditis and autoimmunization. J Am Med Assoc 1957; 164: 1439-47.
9. Rose NR, Bona C. Defining criteria for autoimmune diseases (Witebsky's postulates revisited). Immunol Today 1993; 14: 426-30.
10. Mayer L. Redefining autoimmunity. Gastroenterology 2003; 125: 1574.
11. McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med 2006; 3: e297.
12. Masters SL, Simon A, Aksentijevich I, Kastner DL. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*). Annu Rev Immunol 2009; 27: 621-68.
13. Chervonsky AV. Influence of microbial environment on autoimmunity. Nat Immunol 2010; 11: 28-35.
14. Chapman RW, Varghese Z, Gaul R, et al. Association of primary sclerosing cholangitis with HLA-B8. Gut 1983; 24: 38-41.
15. Prochazka EJ, Terasaki PI, Park MS, Goldstein LI, Busuttil RW. Association of primary sclerosing cholangitis with HLA-DRw52a. N Engl J Med 1990; 322: 1842-4.
16. Karlsen TH, Franke A, Melum E, et al. Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology 2010; 138: 1102-11.
17. Melum E, Franke A, Schramm C, et al. Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. Nat Genet 2011; 43: 17-9.
18. Tervaert JW, Mulder AH, Horst G, et al. Antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis, ulcerative colitis, and autoimmune diseases. Gastroenterology 1992; 102: 1090-1.
19. Xu B, Broome U, Ericzon BG, Sumitran-Holgersson S. High frequency of autoantibodies in patients with primary sclerosing cholangitis that bind biliary epithelial cells and induce expression of CD44 and production of interleukin 6. Gut 2002; 51: 120-7.
20. Mendes FD, Jorgensen R, Keach J, et al. Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol 2006; 101: 2070-5.
21. Alberti-Flor JJ, Jeffers L, Schiff ER. Primary sclerosing cholangitis occurring in a patient with systemic lupus erythematosus and diabetes mellitus. Am J Gastroenterol 1984; 79: 889-91.
22. Gluch J, Glaser J. Primary sclerosing cholangitis, ulcerative colitis and type 1 diabetes mellitus. Z Gastroenterol 1999; 37: 735-8.
23. Katsanos KH, Saougos V, Kosmidou M, et al. Sjogren's syndrome in a patient with ulcerative colitis and primary sclerosing cholangitis: case report and review of the literature. J Crohns Colitis 2009; 3: 200-3.
24. Saarinen S, Olerup O, Broome U. Increased frequency of autoimmune diseases in patients with primary sclerosing cholangitis. Am J Gastroenterol 2000; 95: 3195-9.
25. Lamberts LE, Janse M, Haagsma EB, van den Berg AP, Weersma RK. Immune-mediated diseases in primary sclerosing cholangitis. Dig Liver Dis 2011; 43: 802-6.
26. Rudolph G, Gotthardt D, Kloters-Plachky P, et al. Influence of dominant bile duct stenoses and biliary infections on outcome in primary sclerosing cholangitis. J Hepatol 2009; 51: 149-55.
27. Gotthardt DN, Rudolph G, Kloters-Plachky P, Kulaksiz H, Stiehl A. Endoscopic dilation of dominant stenoses in primary sclerosing cholangitis: outcome after long-term treatment. Gastrointest Endosc 2010; 71: 527-34.
28. Shorbagi A, Bayraktar Y. Primary sclerosing cholangitis-what is the difference between east and west? World J Gastroenterol 2008; 14: 3974-81.
29. Toy E, Balasubramanian S, Selmi C, Li CS, Bowlus CL. The prevalence, incidence and natural history of primary sclerosing cholangitis in an ethnically diverse population. BMC Gastroenterol 2011; 11: 83.
30. Lohse AW, Weiler-Normann C, Tiegs G. Immune-mediated liver injury. J Hepatol 2010; 52: 136-44.
31. Quintana JO, Garcia-Compean D, Gonzalez JA, et al. The impact of diabetes mellitus in mortality of patients with compensated liver cirrhosis-a prospective study. Ann Hepatol 2011; 10: 56-62.
32. Schramm C, Lohse AW. Overlap syndromes of cholestatic liver diseases and auto-immune hepatitis. Clin Rev Allergy Immunol 2005; 28: 105-14.
33. Bamias G, Cominelli F. Immunopathogenesis of inflammatory bowel disease: current concepts. Curr Opin Gastroenterol 2007; 23: 365-9.
34. Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 390-407.
35. Rabinovitz M, Gavaler JS, Schade RR, et al. Does primary sclerosing cholangitis occurring in association with inflammatory bowel disease differ from that occurring in the absence of inflammatory bowel disease? A study of sixty-six subjects. Hepatology 1990; 11: 7-11.
36. Rudolph G, Gotthardt D, Kloeters-Plachky P, et al. In PSC with dominant bile duct stenosis, IBD is associated with an increase of carcinomas and reduced survival. J Hepatol 2010; 53: 313-7.